Drugs / 2-FLUOROFUCOSE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02952989 | Feb 2017 → Jun 2019 | breast neoplasm, colorectal neoplasm, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma +4 | Seagen Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-FLUOROFUCOSE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297429 ↗ |
| Known as | SGN-2FF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02952989 ↗ |
| Modality | Small molecule | — CHEMBL4297429 ↗ |
| Route | Oral | “SGN-2FF oral daily dosing.” NCT02952989 ↗ |